Eloralintide vs Semaglutide | GLP-1R/GCGR vs GLP-1R only | QSC
Eloralintide vs Semaglutide
GLP-1R/GCGR Dual Agonist vs GLP-1R only — Mechanism, Data & Research Application Comparison | QSC
Factor
Eloralintide
Semaglutide
Class
Dual GLP-1R/GCGR Agonist
GLP-1R only
Mechanism
GLP-1R + GCGR co-agonism
GLP-1R monoagonist
Best Trial Result
~10–11% wt loss · ~40–50% liver fat ↓
−14.9% (STEP 1, 68w)
NASH / Liver Data
✓ Phase 2 — direct GCGR/CPT1A
Secondary via weight loss
GCGR Component
✓ Direct hepatic fat oxidation
✗
At QSC
✓ In stock — first mover
✓ In stock
Research Analysis: Eloralintide adds GCGR to the GLP-1R mechanism. The critical research difference: semaglutide reduces liver fat secondarily via weight-loss-driven reduction in adipose lipolysis. Eloralintide reduces liver fat directly via GCGR/CPT1A hepatic fatty acid β-oxidation — independent of body weight changes. For NASH research requiring direct hepatic fat mechanism: eloralintide. For GLP-1R reference pharmacology or cardiovascular research (SELECT trial): semaglutide.
What is the difference between eloralintide and Semaglutide?
Eloralintide is a dual GLP-1R/GCGR co-agonist; Semaglutide is a GLP-1R only. The key mechanistic difference is the presence or absence of GCGR: eloralintide’s GCGR agonism drives direct hepatic CPT1A-mediated fat oxidation — independent of body weight loss. Eloralintide adds GCGR to the GLP-1R mechanism. The critical research difference: semaglutide reduces liver fat secondarily via weight-loss-driven reduction in adipose lipolysis. Eloralintide reduces liver fat directly via GCGR/CPT1A hepatic fatty ac
Which is better for NASH research: eloralintide or Semaglutide?
For research specifically targeting direct hepatic fat oxidation via GCGR/CPT1A, eloralintide is the dedicated tool — Phase 2 data shows ~40–50% liver fat reduction, disproportionate to ~10–11% weight loss. Semaglutide reduces liver fat secondarily via weight loss without a direct GCGR hepatic mechanism.
Are both eloralintide and Semaglutide available at QSC?
Yes — both eloralintide and Semaglutide are available at QSC (qscpeptide.com) at ≥99% HPLC purity with Janoshik independent COA verification. US Domestic Warehouse, 2–4 business day delivery. Researchers can source both compounds from one verified supplier for comparative protocols.
Research Use Only: Eloralintide is sold by QSC strictly for in vitro laboratory research purposes only. Not for human or veterinary use. Not FDA approved for clinical use.
